We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock

Delisted

NBSE was delisted on the 10th of May, 2024.

6 hedge funds and large institutions have $167K invested in NeuBase Therapeutics, Inc. Common Stock in 2013 Q2 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
6
Holders Change
+6
Holders Change %
% of All Funds
0.2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
FNBT
1
FineMark National Bank & Trust
Florida
$125K +$125K +39 New
U
2
UBS
Switzerland
$13K +$12.9K +4 New
Deutsche Bank
3
Deutsche Bank
Germany
$12K +$12.9K +4 New
First Manhattan
4
First Manhattan
New York
$10K +$12.9K +4 New
TRCT
5
Tower Research Capital (TRC)
New York
$4K +$3.21K +1 New
Wells Fargo
6
Wells Fargo
California
$3K +$3.21K +1 New

NBSE Hedge Fund Activity: Q2 2013 in Review

6 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2013, worth a combined $167K.

Buyers outnumbered sellers: 6 funds opened new NBSE positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.

  • 6 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $167K of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2013.
  • 6 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2013 and 0 closed out, a net change of +6 holders.

Based on aggregated 13F filings for Q2 2013.